Referencia número: HY-12833

AMZ30

1 Cited Publications

Revisión del cliente

Based on 1 publication(s) in Google Scholar

AMZ30 is selective protein phosphatase methylesterase-1(PME-1) inhibitor with IC₅₀s of 600 nM and 3.5 µM in human cell lysates and in HEK 293T cells, respectively. AMZ30 shows >100-fold selectivity relative to other serine hydrolases. AMZ30 reduces the demethylated form of PP2A in living cells. AMZ30 attenuates muscle cell differentiation. AMZ30 increases the resistance of U87MG and U251MG glioblastoma cells to t-BHP-induced oxidative stress. AMZ30can be used for the study of glioblastoma.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.10%
No. CAS: 1313613-09-0
Fòrmula: C₁₉H₁₂FN₃O₆S₂
Peso molecular:461.44

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

AMZ30 Chemical Structure

No. CAS: 1313613-09-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Solvente y solubilidad
- In Vitro
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Ver todos los productos específicos de isoformas Akt :

Ver todos los productos específicos de isoformas ERK :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK-293T	IC₅₀	3.5 μM Compound: 28, AMZ30	Inhibition of PME1 binding to FP-rhodamine in HEK293T cells after 1 hr by fluorescence polarization activity-based protein profiling assay Inhibition of PME1 binding to FP-rhodamine in HEK293T cells after 1 hr by fluorescence polarization activity-based protein profiling assay	[PMID: 21639134]
HEK-293T	IC₅₀	600 nM Compound: 28, AMZ30	Inhibition of PME1 binding to FP-rhodamine in human HEK293T cells after 45 mins by fluorescence polarization activity-based protein profiling assay Inhibition of PME1 binding to FP-rhodamine in human HEK293T cells after 45 mins by fluorescence polarization activity-based protein profiling assay	[PMID: 21639134]

In Vitro

AMZ30 (50 μM, 24 h) treatment of C2C12 cells significantly inhibits the expression of muscle cell differentiation markers myosin heavy chain (MyHC) and myogenin during differentiation, while moderately but significantly increasing the level of the PP2A catalytic subunit^[1].
AMZ30 (10-40 μM, 24 h) treatment of C2C12 cells transfected with the AP-1 reporter gene significantly reduces AP-1 reporter gene activity^[1].
AMZ30 (50 μM, 24 h) mediates inhibition of Ppme1 and attenuates MAP kinase signaling in C2C12 cells^[1].
AMZ30 (20 μM, 1 h pretreatment) increases the resistance of U87MG and U251MG glioblastoma cells to t-BHP-induced oxidative stress^[2].
AMZ30 (20 μM, 1 h pretreatment) abolishes the sensitizing effect of PME-1 overexpression in U87MG cells and eliminates the increased sensitivity of U251MG shGFP cells to t-BHP-induced oxidative stress^[2].
AMZ30 (20 μM, 1 h) significantly reduces the demethylated form of PP2A and increases the methylated form in HEK 293T cells stably overexpressing PME-1^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

C2C12 cells
Concentration:

50 μM
Incubation Time:

24 h
Result:

Inhibited the expression of muscle cell differentiation markers myosin heavy chain (MyHC) and myogenin.
Increased the level of the PP2A catalytic subunit.
Reduced the phosphorylation levels of ERK1/2 and p38.
Increased c-Jun protein level without a significant change in the ratio of phosphorylated c-Jun to total c-Jun.
Reduced the phosphorylation status of Akt.

Chemical Information

No. CAS 1313613-09-0
Appearance Solid
Peso molecular 461.44
Fòrmula C₁₉H₁₂FN₃O₆S₂
SMILES

O=S(C1=CC([N+]([O-])=O)=CC=C1)(N2C(/C=C(S(=O)(C3=CC=C(F)C=C3)=O)\C#N)=CC=C2)=O
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All WB

Sort by:

Journal Impact Factor

Front Aging Neurosci

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein. [Abstract]

2018 Jun 8:10:173. PMID: 29950985

AMZ30 purchased from MedChemExpress. Usage Cited in: Front Aging Neurosci. 2018 Jun 8:10:173. [Abstract]

Immunoblotting and quantifications of deMe-PP2A, total-PP2A, p-α-syn, α-syn, and Flag-LCMT-1 in vector, α-syn, α-syn+LCMT-1, α-syn+AMZ30, α-syn+PP2Ac, and α-syn+siPME-1 group. β-tubulin is used as a loading control.

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (216.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1671 mL

10.8356 mL

21.6713 mL

5 mM

0.4334 mL

2.1671 mL

4.3343 mL

10 mM

0.2167 mL

1.0836 mL

2.1671 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (283 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Labuzan SA, et al. Inhibition of protein phosphatase methylesterase 1 dysregulates MAP kinase signaling and attenuates muscle cell differentiation. Gene. 2020 May 20;739:144515. [Content Brief]

[2]. Guffens L, et al. PME-1 sensitizes glioblastoma cells to oxidative stress-induced cell death by attenuating PP2A-B55α-mediated inactivation of MAPKAPK2-RIPK1 signaling. Cell Death Discov. 2023 Jul 27;9(1):265. [Content Brief]

[3]. Bachovchin DA, et al. Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. J Med Chem. 2011 Jul 28;54(14):5229-36. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1671 mL	10.8356 mL	21.6713 mL	54.1782 mL
	5 mM	0.4334 mL	2.1671 mL	4.3343 mL	10.8356 mL
	10 mM	0.2167 mL	1.0836 mL	2.1671 mL	5.4178 mL
	15 mM	0.1445 mL	0.7224 mL	1.4448 mL	3.6119 mL
	20 mM	0.1084 mL	0.5418 mL	1.0836 mL	2.7089 mL
	25 mM	0.0867 mL	0.4334 mL	0.8669 mL	2.1671 mL
	30 mM	0.0722 mL	0.3612 mL	0.7224 mL	1.8059 mL
	40 mM	0.0542 mL	0.2709 mL	0.5418 mL	1.3545 mL
	50 mM	0.0433 mL	0.2167 mL	0.4334 mL	1.0836 mL
	60 mM	0.0361 mL	0.1806 mL	0.3612 mL	0.9030 mL
	80 mM	0.0271 mL	0.1354 mL	0.2709 mL	0.6772 mL
	100 mM	0.0217 mL	0.1084 mL	0.2167 mL	0.5418 mL

Keywords

AMZ30

1 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

AMZ30

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Phosphatase Inhibitor Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) AMZ30

Ver todos los productos específicos de isoformas Akt

Ver todos los productos específicos de isoformas ERK

Actividad biológica

Chemical Information

Publications (1)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

AMZ30 Related Classifications

HY-12833 Related Classifications